Adalimumab effect on COVID-19

Evaluation of adalimumab effect on clinical symptoms including respiratory distress, oxygen saturation and lung involvement of patients with COVID-19

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20171105037262N4

Enrollment

100

Registered

2020-06-18

Start date

2020-04-29

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: 50 patients with COVID-19 who receive routine antiviral treatment and chloroquine, have more than normal levels of TNF-a, and are at risk of critical disease statem

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Having COVID-19 Respiratory distress with over 30 breaths per minute O2 saturation less than 93% at rest PaO2/Fio2 less than 300 mmHg HRCT indicating COVID-19 positive PCR test result

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Disease severity. Timepoint: At the beginning and end of the intervention. Method of measurement: According to protocol and clinical symptoms.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHassan Nikoueinejad

Bagheiat-allah University of Medical Sciences

hnikuinejad@yahoo.com+98 21 8755 5250

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026